GABAB receptor intracellular signaling: novel pathways for depressive disorder treatment?

Eur J Pharmacol. 2020 Oct 15:885:173531. doi: 10.1016/j.ejphar.2020.173531. Epub 2020 Aug 29.

Abstract

Affecting over 320 million people around the world, depression has become a formidable challenge for modern medicine. In addition, an increasing number of studies cast doubt on the monoamine theory of depressive disorder and, worryingly, antidepressant medications only significantly benefit patients with severe depression. Thus, it is not surprising that researchers have shown an increased interest in new theories attempting to explain the pathogenesis of this disease. One example is the excitatory/inhibitory transmission imbalance theory. These abnormalities involve glutamate and γ-aminobutyric acid (GABA) signaling. Studies on GABAB receptors and their antagonists are particularly promising for the treatment of depressive disorders. In this paper, intracellular pathways controlled by GABAB receptors and their links to depression are described, including the impact of ketamine on GABAergic synaptic transmission.

Keywords: Antidepressant drugs; Depression; Ion channels; Neuroplasticity; Neurotransmitters; Receptors.

Publication types

  • Review

MeSH terms

  • Animals
  • Antidepressive Agents / pharmacology*
  • Depressive Disorder / drug therapy*
  • Humans
  • Intracellular Signaling Peptides and Proteins / drug effects
  • Intracellular Signaling Peptides and Proteins / physiology*
  • Receptors, GABA-B / drug effects*
  • Receptors, GABA-B / physiology*
  • Signal Transduction / drug effects*
  • gamma-Aminobutyric Acid / physiology

Substances

  • Antidepressive Agents
  • Intracellular Signaling Peptides and Proteins
  • Receptors, GABA-B
  • gamma-Aminobutyric Acid